Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes

International Journal of Obesity

Volumn 24, Issue , 2000, Pages S38-S44

  Landgraf, R ^a   Frank, M ^b   Bauer, C ^c   Leyck Dieken, M ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Ev Fliedner Krankenhaus   (Germany)

^c Novo Nordisk Pharma GmbH   (Germany)

Author keywords

Lifestyle; Prandial glucose regulation; Repaglinide; Type 2 diabetes

Indexed keywords

ACARBOSE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; GERMANY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ATTITUDE TO HEALTH; BLOOD GLUCOSE; CARBAMATES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; EATING; FEMALE; FOOD HABITS; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; MIDDLE AGED; PIPERIDINES; PROFESSIONAL PRACTICE; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 0033799522     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801424     Document Type: Article

References (35)

1. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988; 37: 736-744.
2. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. New Engl J Med 1988; 318: 1231-1239.
3. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM. Diabetes 1990; 39: 1381-1390.
4. Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the ‘natural history’ of established Type 2 (noninsulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177-187.
5. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabetic Med 1996; 13(Suppl 6): S19-S24.
6. Home PD. Rapid-acting insulin secretagogues: a clinical need? Exp Clin Endocrinol Diabetes 1999; 107(Suppl 4): S115-S119.
7. Haller H. Postprandial glucose and vascular disease. Diabetic Med 1997; 14(Suppl): S50-S56.
8. Haller H. The clinical importance of postprandial glucose. Diabetes Res Clin Pract 1998; 40(Suppl): S43-S49.
9. Ceriello A. The emerging role of post-prandial hyper-glycaemic spikes in the pathogenesis of diabetic complications. Diabetic Med 1998; 15: 188-193.
10. Haffner SM. The importance of hyperglycaemia in the nonfasting state to the development of cardiovascular disease. EndocrRev 1998; 19: 583-592.
11. Lefèbvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabetic Med 1998; 15(Suppl 4): S63-S68.
12. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, The DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
13. Balkau B, Shipley M, Jarrett RJ. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360-367.
14. Tominaga M, Igarishi K, Eguchi H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999; 22: 920-924.
15. DECODE study group, European Diabetes Epidemiology group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
16. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 1998; 34: 181-188.
17. Zhou DB, Ipp E. Sulphonylurea effects on insulin secretion in islets desensitized to glucose. Pancreas 1990; 5: 528-532.
18. Fuhlendorff J, Rorsman P, Kofod H et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
19. Anello M, Gilon P, Henquin JC. Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. Br J Pharmacol 1999; 127: 1883-1891.
20. Owens DR. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drug. Diabetic Med 1998; 15(Suppl 4): S28-S36.
21. Landgraf R. Approaches to the management of postprandial hyperglycaemia. Exp Clin Endocrinol Diabetes 1999; 107(Suppl 4): S128-S132.
22. Landgraf R. Meglitinides in the treatment of Type 2 diabetes mellitus. Drugs & Aging (in press).
23. van Gaal LF, van Acker KL, Damsbo P, De Leeuw IH. Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-na'ive Type 2 diabetics. Diabetologia 1995; 38(Suppl 1): A43.
24. Goldberg RB, Einhorn D, Luca CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG. A randomized placebocontrolled trial of repaglinide in the treatment of Type 2 diabetes. Diabetes Care 1998; 21: 1897-1903.
25. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in Type 2 diabetes: a 24 week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57.
26. Damsbo P, Clauson P, Marbury TC, Windfeld K. A doubleblind randomised comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled Type 2 diabetic patients. Diabetes Care 1999; 22: 789-794.
27. Damsbo P, Marbury TC, Hatorp V, Clauson P, Müller PG. Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-39.
28. Dejgaard A, Madsbad S, Kilhovd B, Lager I, Mustajoki P. Repaglinide compared to glipizide in the treatment of Type 2 diabetic patients. Diabetologia 1998; 41(Suppl 1): A236.
29. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of Type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-467.
30. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155-166.
31. Landgraf R, Bilo HJ, Müller PG. A comparison of repaglinide and glibenclamide in the treatment of Type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55: 165-171.
32. Smedegaard Kristensen J, Brown Frandsen K, Bayer T, Müller PG. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylureas. Diabetologia 1999; 42(Suppl 1): A4.
33. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repagli-nide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 1999; 22: 19-24.
34. Nattrass M, Lauritzen T. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypogly-caemia in the treatment of Type 2 diabetes? Int J Obes Relat Metab Disord 2000; 24(Suppl 3): S21-S31.
35. Brown Frandsen K, Smedegaard Kristensen J. Compliance with, and understanding of, mealtime advice in patients with Type 2 diabetes. Diabetes 2000; 49(Suppl 1): A176.